EXPERIMENTAL, PHARMAKOKINETIC AND CLINICA L-EVALUATION OF IP THERAPY WITH INTERLEUKIN-2 (NIL-2) IN PATIENTS WITH OVARIAN-CANCER

Authors
SCHRODER W SCHWULERA U LISSNER R BENDER HG
Citation
W. Schroder et al., EXPERIMENTAL, PHARMAKOKINETIC AND CLINICA L-EVALUATION OF IP THERAPY WITH INTERLEUKIN-2 (NIL-2) IN PATIENTS WITH OVARIAN-CANCER, Gynakologisch-geburtshilfliche Rundschau, 35, 1995, pp. 46-52
Citations number
28
Categorie Soggetti
Obsetric & Gynecology
Journal title
Gynakologisch-geburtshilfliche Rundschau → ACNP
ISSN journal
10188843
Volume
35
Year of publication
1995
Supplement
1
Pages
46 - 52
Database
ISI
SICI code
1018-8843(1995)35:<46:EPACLO>2.0.ZU;2-B
Abstract
Objective: In an orthotopic transplantation model using human ovarian cancer xenografts we evaluated antitumor effects of nIL-2 as well as i ts side effects in a clinical phase I/II study. Methods: In patients w ith advanced ovarian cancer nIL-2 was administered i.p. in escalating doses every two days by means of a Tenckhoff-catheter. Results: Consid erable stimulation of intraperitoneal immune cells was observed withou t severe toxic side effects WHO grade III/IV. Conclusion: Due pharmaco logical-pharmacokinetic advantages using the i.p. route nIL-2 was very well tolerated and showed considerable stimulation of local immune ce lls.